Unified Investment Management Buys Shares of 18,725 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Unified Investment Management acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 18,725 shares of the biopharmaceutical company's stock, valued at approximately $895,000.

A number of other hedge funds also recently bought and sold shares of the company. Heck Capital Advisors LLC acquired a new position in Halozyme Therapeutics during the 4th quarter worth approximately $29,000. Smartleaf Asset Management LLC increased its position in shares of Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 197 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $69,000. Parkside Financial Bank & Trust increased its holdings in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 322 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its position in Halozyme Therapeutics by 173.6% in the third quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company's stock valued at $93,000 after purchasing an additional 1,028 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the transaction, the senior vice president now owns 185,453 shares in the company, valued at $10,765,546.65. The trade was a 5.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total transaction of $293,450.00. Following the sale, the director now directly owns 33,611 shares of the company's stock, valued at approximately $1,972,629.59. This represents a 12.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 31,697 shares of company stock valued at $1,754,451 in the last ninety days. 2.40% of the stock is currently owned by company insiders.

Remove Ads

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on HALO. Wells Fargo & Company reduced their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Benchmark reissued a "buy" rating and set a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Piper Sandler increased their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. Finally, HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $62.78.

Halozyme Therapeutics Price Performance

NASDAQ:HALO traded up $0.62 during trading hours on Thursday, reaching $60.15. 1,753,268 shares of the company traded hands, compared to its average volume of 1,303,077. The stock has a market cap of $7.41 billion, a P/E ratio of 17.54, a P/E/G ratio of 0.42 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $65.53. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The firm's 50-day moving average is $55.20 and its 200-day moving average is $54.74.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.